Literature DB >> 1970815

Use of clonazepam for bipolar affective disorder.

G S Sachs1.   

Abstract

The use of anticonvulsants as treatments for bipolar affective disorder is growing, and despite relatively scant data, anticonvulsants have become widely accepted as adjuncts to lithium therapy, particularly as alternatives to neuroleptics. Although most of the research work to date has involved carbamazepine, improvement in bipolar symptoms with clonazepam has been exhibited in controlled studies and case reports. The author summarizes studies done by the Bipolar Research Group of the Clinical Psychopharmacology Unit at Massachusetts General Hospital. The data thus far indicate that clonazepam can be added to the treatment regimen of bipolar patients and apparently reduces cycle frequency; many patients using neuroleptics and lithium can be switched to lithium and clonazepam without suffering acute relapse; and clonazepam may be associated with fewer depressive recurrences than neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970815

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  14 in total

1.  Extreme attributions predict suicidal ideation and suicide attempts in bipolar disorder: prospective data from STEP-BD.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; David J Miklowitz; Michael W Otto; Ellen Frank; Michael Berk; Natasha S Hansen; Darin D Dougherty; Andrew A Nierenberg; Thilo Deckersbach
Journal:  World Psychiatry       Date:  2014-02       Impact factor: 49.548

2.  Complex polypharmacy in bipolar disorder: Side effect burden, adherence, and response predictors.

Authors:  Vicki C Fung; Lindsay N Overhage; Louisa G Sylvia; Noreen A Reilly-Harrington; Masoud Kamali; Keming Gao; Richard C Shelton; Terence A Ketter; William V Bobo; Michael E Thase; Joseph R Calabrese; Mauricio Tohen; Thilo Deckersbach; Andrew A Nierenberg
Journal:  J Affect Disord       Date:  2019-07-02       Impact factor: 4.839

Review 3.  A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis.

Authors:  R F Squires; E Saederup
Journal:  Neurochem Res       Date:  1991-10       Impact factor: 3.996

4.  Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program.

Authors:  David J Miklowitz; Michael W Otto; Ellen Frank; Noreen A Reilly-Harrington; Stephen R Wisniewski; Jane N Kogan; Andrew A Nierenberg; Joseph R Calabrese; Lauren B Marangell; Laszlo Gyulai; Mako Araga; Jodi M Gonzalez; Edwin R Shirley; Michael E Thase; Gary S Sachs
Journal:  Arch Gen Psychiatry       Date:  2007-04

5.  Extreme attributions predict transition from depression to mania or hypomania in bipolar disorder.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; Ellen Frank; Michael W Otto; David J Miklowitz; Michael Berk; Andrew A Nierenberg; Thilo Deckersbach
Journal:  J Psychiatr Res       Date:  2013-06-21       Impact factor: 4.791

6.  Do Sleep Disturbances Predict or Moderate the Response to Psychotherapy in Bipolar Disorder?

Authors:  Louisa G Sylvia; Stephanie Salcedo; Amy T Peters; Pedro Vieira da Silva Magalhães; Ellen Frank; David J Miklowitz; Michael W Otto; Michael Berk; Andrew A Nierenberg; Thilo Deckersbach
Journal:  J Nerv Ment Dis       Date:  2017-03       Impact factor: 2.254

7.  Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial.

Authors:  David J Miklowitz; Michael W Otto; Ellen Frank; Noreen A Reilly-Harrington; Jane N Kogan; Gary S Sachs; Michael E Thase; Joseph R Calabrese; Lauren B Marangell; Michael J Ostacher; Jayendra Patel; Marshall R Thomas; Mako Araga; Jodi M Gonzalez; Stephen R Wisniewski
Journal:  Am J Psychiatry       Date:  2007-09       Impact factor: 18.112

8.  Development of the Bipolar Inventory of Symptoms Scale: concurrent validity, discriminant validity and retest reliability.

Authors:  Jodi M Gonzalez; Charles L Bowden; Martin M Katz; Peter Thompson; Vivek Singh; Thomas J Prihoda; Martha Dahl
Journal:  Int J Methods Psychiatr Res       Date:  2008       Impact factor: 4.035

Review 9.  Bipolar spectrum disorders. New perspectives.

Authors:  Andre Piver; Lakshmi N Yatham; Raymond W Lam
Journal:  Can Fam Physician       Date:  2002-05       Impact factor: 3.275

10.  Affective instability and the course of bipolar depression: results from the STEP-BD randomised controlled trial of psychosocial treatment.

Authors:  Jonathan P Stange; Louisa G Sylvia; Pedro Vieira da Silva Magalhães; David J Miklowitz; Michael W Otto; Ellen Frank; Christine Yim; Michael Berk; Darin D Dougherty; Andrew A Nierenberg; Thilo Deckersbach
Journal:  Br J Psychiatry       Date:  2016-01-21       Impact factor: 9.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.